Aphria (APHA) Sign Deal to Develop Cannabis Transdermal Patches

Aphria (TSX: APHA) (NYSE: APHA) said it has signed a worldwide license agreement with Manna Molecular Science to develop and sell cannabis transdermal patches.

Under the agreement, Aphria will use Manna’s formulations, equipment and processes to produce and sell patches containing cannabis oils for its established suite of medical and adult-use brands.

Licensing Deal 

Under the agreement, Manna grants Aphria an exclusive preferred vendor status for a period of five years.

The company also gives Aphria an exclusive license to produce, market, distribute, promote and sell Manna patches containing cannabis oil as an active ingredient.

“Aphria gives Manna the reach to distribute the Manna patch at a global level and share our principles of excellence in product design and manufacturing with the world outside the U.S.,” Manna Molecular Science CEO Nial DeMena said in a press statement.

Manna Cannabis Transdermal Patch

The Manna cannabis transdermal patch has been developed by pharmaceutical scientists from the Massachusetts Institute of Technology using state-of-the-art product design and research methods.

The patch works for all cannabinoids and is designed to work with whole-plant cannabis extracts, which are printed on each patch with pharmaceutical quality.

Each patch is latex- and allergen-free and delivers the dose automatically through the skin over the course of 12 hours.

“As we continue to expand its use from product to ingredient, we are excited to offer innovative new ways for consumers to interact with cannabis,” Aphria President Jakob Ripshtein stated. “As a company at the forefront of cannabis innovation, Manna Molecular Science will be an important strategic partner for Aphria.”